67
Pharma & HealthcareBuy
DSP Healthcare
DSP · Direct–Growth · rank #5 of 19 by Smart Score
Data updated
Trailing returns
1 Year
12.6%
+17.3% vs index
3 Years
19.5%
+10.1% vs index
5 Years
14.8%
+6.8% vs index
Since launch
22.2%
Year-by-year performance
2021
+25.1%-5.5% vs index
2022
-6.5%-10.3% vs index
2023
+36.8%+10.3% vs index
2024
+42.6%+27.0% vs index
2025
-4.5%-12.2% vs index
2026
+12.1%+18.1% vs index
Why this score
DSP Healthcare scores 67/100 — #5 of 19 Pharma & Healthcare fund (Buy). It stands out for 5y return and sharpe ratio — beating 72% of peers on 5y return. It has no major weak spot vs the category.
Each bar shows the fund's percentile vs Pharma & Healthcare peers — a longer bar beats more of the category.
5Y return14.76% · 72nd percentile in category
Sharpe ratio0.98 · 78th percentile in category
Expense ratio0.75% · 87th percentile in category
Fund size3750.04 Cr · 82nd percentile in category
Sortino ratio1.42 · 70th percentile in category
Alpha4.56 · 66th percentile in category
Top holdings
1.Ipca Laboratories Ltd8.13%
2.Sun Pharmaceutical Industries Ltd7.44%
3.Cipla Ltd7.18%
4.Sai Life Sciences Ltd.6.52%
5.Gland Pharma Ltd6.15%
31 disclosed equity positions · portfolio as of Sept 2026 · weights are % of total corpus.